Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1652-1658

  Koizumi, Keiichi ^a   Hojo, Shozo ^a   Akashi, Takuya ^a   Yasumoto, Kazuo ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTIANDROGEN; APC PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CXCR4; NAVELBINE; SMAD4 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TAXANE DERIVATIVE; TE 14003; TE 14011; TRASTUZUMAB; UNCLASSIFIED DRUG;

BONE MARROW CELL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GENE MUTATION; GENETIC CODE; HUMAN; LEUKOCYTE MIGRATION; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; STROMA CELL; SURVIVAL RATE; SURVIVAL TIME;

CHEMOKINE CXCL12; CHEMOKINES; CHEMOTAXIS; DISEASE PROGRESSION; HUMANS; LEUKOCYTES; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4;

EID: 34748820033     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00606.x     Document Type: Review

References (71)

1. Yoshie O, Imai T, Nomiyama H. Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 1997; 62: 634-44.
2. Yoshie O. Immune chemokines and their receptors: The key elements in the genesis, homeostasis and function of the immune system. Springer Semin Immunopathol 2000; 22: 371-91.
3. Zlotnik A. Chemokines and cancer. Int J Cancer 2006; 119: 2026-9.
4. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96: 317-22.
5. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
6. Koizumi K, Kozawa Y, Ohashi Y et al. CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncol Rep 2007; 17: 1511-16.
7. Nakamura ES, Koizumi K, Kobayashi M et al. RANKL-induced CCL22/ macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 2006; 23: 9-18.
8. Yasumoto K, Koizumi K, Kawashima A et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 2006; 66: 2181-7.
9. Akashi T, Koizumi K, Nagakawa O, Fuse H, Saiki I. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145. Oncol Rep 2006; 16: 831-6.
10. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and melanoma metastasis. J Dermatol Sci 2004; 36: 71-8.
11. Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med 2006; 6: 685-93.
12. Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 1998; 273: 4754-60.
13. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/ SDF-1. Nature 1996; 382: 635-8.
14. Slettenaar VI, Wilson JL. The chemokine network: A target in cancer biology? Adv Drug Deliv Rev 2006; 58: 962-74.
15. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-9.
16. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003; 5: 144-50.
17. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 2002; 62: 1832-7.
18. Oonakahara K, Matsuyama W, Higashimoto I et al. Stromal-derived factor-1α/CXCL12-CXCR4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 2004; 30: 671-7.
19. Scotton CJ, Wilson JL, Scott K et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-8.
20. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res 2001; 61: 4961-5.
21. Saur D, Seidler B, Schneider G et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005; 129: 1237-50.
22. Scala S, Ottaiano A, Ascierto PA et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11: 1835-41.
23. Russell HV, Hicks J, Okcu MF, Nuchtern JG. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 2004; 39: 1506-11.
24. Kaifi JT, Yekebas EF, Schurr P et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-7.
25. Kim J, Takeuchi H, Lam ST et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-53.
26. Oda Y, Yamamoto H, Tamiya S et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006; 19: 738-45.
27. Pan J, Mestas J, Burdick MD et al. Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 2006; 3: 56-69.
28. Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981; 12: 237-42.
29. Maehara Y, Moriguchi S, Kakeji Y et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991; 110: 820-3.
30. Takahashi I, Matsusaka T, Onohara T et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 2000; 47: 1485-8.
31. Bando E, Yonemura Y, Takeshita Y et al. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-62.
32. Spano JP, Andre F, Morat L et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: Pattern of expression and correlation with outcome. Ann Oncol 2004; 15: 613-17.
33. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: A possible role for tumor progression. Clin Cancer Res 2000; 6: 3530-5.
34. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006; 103: 226-33.
35. Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-69.
36. Debruyne F. Hormonal therapy of prostate cancer. Semin Urol Oncol 2002; 20 (3 Suppl 1): 4-9.
37. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
38. Murakami T, Maki W, Cardones AR et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62: 7328-34.
39. Sun YX, Schneider A, Jung Y et al. Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-29.
40. De Clercq E. Potential clinical applications of the CXCR4 antagonist Bicyclam AMD3100. Mini Rev Med Chem 2005; 5: 805-24.
41. Retz M, Sidhu SS, Lehmann J, Tamamura H, Fujii N, Basbaum C. New HIV-drug inhibits in vitro bladder cancer migration and invasion. Eur Urol 2005; 48: 1025-30.
42. Takenaga H, Tamamura K, Hiramatsu N et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004; 320: 226-32.
43. Mori R, Doi M, Koizumi ET et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther 2004; 3: 29-37.
44. Liang Z, Wu T, Lou H et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302-8.
45. Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006; 11 (Suppl 1): 34-41.
46. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
47. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002; 13: 143-54.
48. Ueno T, Toi M, Saji H et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-9.
49. Luboshits G, Shina S, Kaplan O et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59: 4681-7.
50. Ueno T, Toi M, Saji H et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002; 102: 220-4.
51. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005; 26: 41-7.
52. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
53. Lamlum H, Papadopoulou A, Ilyas M et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA 2000; 97: 2225-8.
54. + myeloid cells that promote invasion. Nat Genet 2007; 39: 467-75.
55. Oshima H, Oshima M, Kobayashi M, Tsutsumi M, Taketo MM. Morphological and molecular processes of polyp formation in ApcΔ716 knockout mice. Cancer Res 1997; 57: 644-9.
56. Yang X, Lu P, Fujii C. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int J Cancer 2006; 118: 1869-76.
57. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997; 182: 318-24.
58. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
59. Shimaoka T, Kume N, Minami M et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000; 275: 40663-6.
60. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185: 2015-23.
61. Wilbanks A, Zondlo SC, Murphy K et al. Expression cloning of the STRL33/ BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001; 166: 5145-54.
62. Hase K, Murakami T, Takatsu H et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006; 176: 43-51.
63. Thomas SY, Hou R, Boyson JE et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 2003; 171: 2571-80.
64. Shimaoka T, Nakayama T, Fukumoto N et al. Cell surface-anchored SR-PSOX/ CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004; 75: 267-74.
65. Hojo S, Koizumi K, Tsuneyama K et al. High-level expression of the chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007; 67: 4725-31.
66. Tada T, Ohzeki S, Utsumi K et al. Transforming growth factor-β-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-82.
67. van Deventer HW, Serody JS, McKinnon KP, Clements C, Brickey WJ, Ting JP. Transfection of macrophage inflammatory protein 1α into B16, F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. J Immunol 2002; 169: 1634-9.
68. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165: 1992-2000.
69. Gao JQ, Tsuda Y, Katayama K et al. Antitumor effect by interleukin-11 receptor α-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res 2003; 63: 4420-5.
70. Guo J, Chen T, Wang B et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003; 89: 1-7.
71. Xin H, Kikuchi T, Andarini S et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005; 35: 1371-80.